SCHEMBL4936394

SCHEMBL4936394

O=C(N[C@@H](Cc1ccccc1)C(=O)NCC1CC(Cl)=NO1)OCc1ccccc1

nearest known ligand 0.75

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
TGM2 P21980 7/20 0.75
CTSL P07711 2/20 0.55
CTSB P07858 2/20 0.55
CTSS P25774 1/20 0.55
CTSK P43235 1/20 0.55
TACR1 P25103 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9825343 1.00 TGM2 (0.75) TGM2CTSLCTSBCTSSCTSK
SCHEMBL4935845 0.96 TGM2 (0.73) TGM2CTSLCTSBCTSSCTSK
SCHEMBL4937443 0.96 TGM2 (0.82) TGM2CTSLCTSBCTSSCTSK
SCHEMBL9825926 0.93 TGM2 (0.69) TGM2CTSLCTSBCTSSCTSK
SCHEMBL9826613 0.93 TGM2 (0.68) TGM2CTSLCTSBCTSSCTSK
SCHEMBL9825959 0.93 TGM2 (0.66) TGM2CTSLCTSBCTSSCTSK
SCHEMBL9825571 0.93 TGM2 (0.66) TGM2CTSLCTSBCTSSCTSK
SCHEMBL4929775 0.93 TGM2 (0.68) TGM2CTSLCTSBCTSSCTSK
SCHEMBL9826302 0.91 TGM2 (0.63) TGM2
SCHEMBL9825280 0.91 TGM2 (0.69) TGM2CTSLCTSBCTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0237082-B1 3,5-DISUBSTITUTED 4,5-DIHYDROISOXAZOLES AS TRANSGLUTAMINASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1991-05-29 EP claimed
US-4929630-A SKIN DISORDERS, ACNE, 4,5-DIHYDROISOOXAZOLE PEPTIDES SYNTEX (U.S.A.) INC. (US) 1990-05-29 US claimed
US-4912120-A Containing amine and amide substitution SYNTEX (U.S.A.) INC. (US) 1990-03-27 US claimed
EP-0237082-A2 3,5-disubstituted 4,5-dihydroisoxazoles as transglutaminase inhibitors SYNTEX (U.S.A.) INC. (US) 1987-09-16 EP claimed
US-20080299170-A1 Medical Devices and Coatings Therefor ASTON UNIVERSITY (GB) 2008-12-04 US disclosed
EP-0237082-B1 3,5-DISUBSTITUTED 4,5-DIHYDROISOXAZOLES AS TRANSGLUTAMINASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1991-05-29 EP disclosed
US-4929630-A SKIN DISORDERS, ACNE, 4,5-DIHYDROISOOXAZOLE PEPTIDES SYNTEX (U.S.A.) INC. (US) 1990-05-29 US disclosed
US-4912120-A Containing amine and amide substitution SYNTEX (U.S.A.) INC. (US) 1990-03-27 US disclosed
EP-0237082-A2 3,5-disubstituted 4,5-dihydroisoxazoles as transglutaminase inhibitors SYNTEX (U.S.A.) INC. (US) 1987-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080299170-A1 Medical Devices and Coatings Therefor F8, HABP2, TFPI TGM2 16/4885CTSL 104/4885CTSB 683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.